GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

Home・Lista de Ações・Novo Nordisk A-S (Class B)

Novo Nordisk A-S (Class B)

Fechado

288.45 1.26

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

286.85

Máximo

289.85

Indicadores-chave
By Trading Economics
Rendimento	22B 49B
Vendas	18B 97B
P/E Médio do Setor	10.403 49.701
EPS	10.91
Rendimento de Dividendos	4.09
Margem de lucro	50.15
Funcionários	67,900
EBITDA	32B 69B

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+9.53% upside

Dividendos
By Dow Jones
Rendimento de Dividendos Médio do Setor	4.09% 2.39%
Próximos Ganhos	5 de ago. de 2026
Próxima data de ex-dividendo	13 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	8.6B 1.3T
Abertura anterior	287.19
Fecho anterior	288.45

Novo Nordisk A-S (Class B) Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de mai. de 2026, 15:48 UTC

Aquisições, Fusões, Aquisições de Empresas

Novo Nordisk to Sell Parkinson's Cell Therapy to Startup Cellular Intelligence

6 de mai. de 2026, 07:30 UTC

Ganhos

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

6 de mai. de 2026, 06:19 UTC

Ganhos

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

18 de mai. de 2026, 13:10 UTC

Conversa de Mercado

Ganhos

Novo Nordisk Report Shows Bright Spots Amid Price Pressure -- Market Talk

12 de mai. de 2026, 12:05 UTC

Ações em Alta

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12 de mai. de 2026, 10:51 UTC

Ações em Alta

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12 de mai. de 2026, 09:42 UTC

Ganhos

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

12 de mai. de 2026, 09:08 UTC

Ações em Alta

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

11 de mai. de 2026, 20:30 UTC

Ganhos

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

7 de mai. de 2026, 09:30 UTC

Ganhos

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6 de mai. de 2026, 12:36 UTC

Ganhos

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6 de mai. de 2026, 10:53 UTC

Ações em Alta

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 de mai. de 2026, 10:12 UTC

Ganhos

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6 de mai. de 2026, 09:58 UTC

Ganhos

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

6 de mai. de 2026, 09:35 UTC

Ações em Alta

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6 de mai. de 2026, 08:13 UTC

Conversa de Mercado

Ganhos

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

6 de mai. de 2026, 07:43 UTC

Conversa de Mercado

Ganhos

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

6 de mai. de 2026, 07:00 UTC

Ganhos

Novo Nordisk Shares Rise 5.5% After 1Q Results

6 de mai. de 2026, 06:34 UTC

Ganhos

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

6 de mai. de 2026, 06:26 UTC

Ganhos

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

6 de mai. de 2026, 06:26 UTC

Ganhos

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

6 de mai. de 2026, 06:24 UTC

Ganhos

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

6 de mai. de 2026, 06:20 UTC

Ganhos

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

6 de mai. de 2026, 06:19 UTC

Ganhos

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

6 de mai. de 2026, 06:13 UTC

Ganhos

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

6 de mai. de 2026, 06:13 UTC

Ganhos

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

6 de mai. de 2026, 06:12 UTC

Ganhos

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

6 de mai. de 2026, 05:43 UTC

Ganhos

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

6 de mai. de 2026, 05:42 UTC

Ganhos

Novo Nordisk: Total Prescriptions For Wegovy Pill in 1Q Reached Around 1.3M

6 de mai. de 2026, 05:40 UTC

Ganhos

Novo Nordisk: First Wegovy Pill Launches Outside U.S. Expected During 2H26

Comparação entre Pares

Variação de preço

Novo Nordisk A-S (Class B) Previsão

Preço-alvo

By TipRanks

9.53% parte superior

Previsão para 12 meses

Média 1,162.73 DKK 9.53%

Máximo 1,550 DKK

Mínimo 720 DKK

Com base em 11 analistas de Wall Street que oferecem metas de preço de 12 meses para Novo Nordisk A-S (Class B) - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

11 ratings

Comprar

Manter

Vender

Com base em 11 analistas que deram avaliações de ações para Novo Nordisk A-S (Class B) - Dist nos últimos 3 meses.

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.